Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial
This appropriately designed study compared two dose levels of enobosarm in patients with ER+, HER2-, and AR+ advanced breast cancer. Enobosarm is an oral selective activator of the AR: the results of this study suggest possibilities of increasing therapeutic options for these patients.
READ THE ARTICLE – https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00004-4/fulltext